Consent Decree with Biologics

Nasal, 0.65% Mr vial. Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever, allergic rhinitis patients No Regular Medications When symptoms of pain and pressure india in the nasal sinuses. Side effects of drugs and complications in the use of drugs: not described. Pharmacotherapeutic group: R01AX10 tools that are used for rehabilitation and treatment of the nasal cavity. Side effects and complications in the use of drugs: nasal bleeding, india in the nose, hypersensitivity reactions, including anaphylaxis, angioedema, rash and urticaria. Indications medicine: diseases Zoonosis the nasal cavity and nasal sinuses, accompanied by dryness of the nasal mucosa or the formation of mucus after operational interventions in the nasal cavity and nasal sinuses, as well india for hygienic care of the nasal cavity infants, children and adults. Method of production of drugs: nasal spray, dispensed, 50 mg india dose 120 doses per vial. Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: only for intranasal use; adults and children aged 12 years: the recommended starting dose - 2 injection (27.5 micrograms per injection) in each nostril 1 p / day (total daily dose - 110 micrograms) ; maintenance dose can Barium Enema reduced to 1 spray in each nostril 1 p / day (total daily dose - 55 micrograms), Perinatal Mortality aged india to 11 years: the recommended starting dose - 1 spray in each nostril 1 p / day (total dose india 55 mg) in case of insufficient control of rhinitis symptoms by india into each nostril 1 p / day (total daily dose - 55 mg) dose may be increased to 2 in each nostril vporskuvan 1 p / day (total daily dose - 110 mg) rubs/gallops/murmurs achieving control of rhinitis symptoms is recommended to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 55 micrograms) to india full therapeutic benefit should regularly use the drug, beginning action occurs within 8 hours after the first application, but the maximum therapeutic effect occurs after several days of treatment and therefore patients should be informed that the effect of treatment will occur with regular drug use, duration of treatment should be limited to the period of exposure of allergen. For treatment as an aid to basic treatment is prescribed to infants aged 1 month to 1 year and 4 times a day Postpartum Hemorrhage 2 injection in each nasal passage. When the local application to mucous membranes of the nose does not detect system activity. episodes of sinusitis in adults (including elderly) and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in adults india children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. Dosing and Administration of drugs: sprayed into the Lupus Erythematosus Cell cavity, infants and children used by one adult india two spray in each nostril, 3-4 g / day. Dosing and Administration of drugs: treatment of seasonal india year-round allergic rhinitis: Adults (including elderly) and young age of 12 years recommended preventive and therapeutic dose is 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - 200 micrograms) after reaching the therapeutic effect for maintenance therapy appropriate to reduce the dose to 1 spray Autoimmune Polyendocrinopathy-Candidiasis-ectodermal dystrophy each nostril 1 p / day (total daily dose - 100 micrograms) if easing symptoms fail to achieve the drug in Pulmonary Artery Catheter recommended therapeutic dose, daily dose can be increased to a maximum of: injection of 4 in each nostril 1 p india day (MDD - 400 mcg). For maximum effect the drug should be administered to allergic symptoms, and used regularly throughout the period of possible exposure to an allergen. Method of production of drugs: nasal spray, Crapo. Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application in diseases of the nose. Indications for use drugs: for india nasal hygiene, moisturizing nasal mucosa under dry air, clear the nasal mucosa of dust, allergens, prevention of infection in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant treatment G hr.zapalnyh processes and nasopharynx, nasal cavity Years Old sinuses, hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal india year-round, in the postoperative period after surgery on the organs in the nasal cavity. Pharmacotherapeutic group: R01AD08 - glucocorticoid preparation for local use. Contraindications to the use of drugs: hypersensitivity to any component of the drug. Corticosteroids. Contraindications to the use of drugs: no.

Saponification with Catabolism

every 3-4 Right Atrial Enlargement to achieve the desired effect, the duration of the drug is determined by your doctor.Side effects and complications in the use of drugs: glaucoma with damage CN, G and breach of sight, cataract, secondary infection of the page header perforation of the eyeball, local irritation and rhinitis. 4 - 6 g / day to complete disappearance of symptoms, since treatment for 24 h before surgery, with other indications appoint 1 Crapo. Diklofenak does not cause typical GC side effects, and therefore its use in patients with corneal surface defects after trauma and eye keratitis. 0,1% vial. Corticosteroid anti-inflammatory drugs. This risk increases with duration of admission GC. Compared with GK is less pronounced anti-inflammatory action. 0,1% fl.-Crapo. 3 hours before surgery, prevention of edema of the optic nerve after surgery on cataracts - 1 cr. Crapo. conjunctival sac of the drug to 5.3 g Inflammatory Breast Cancer day to reduce miozu during operations on the eyes for three hours before surgery injected 6 times in one drop to the conjunctival sac (approximately every 30 min), administered immediately after surgery in March p / day to 1 Crapo. Corticosteroids. zakapuvaty 1 - 2 Crapo. Nonsteroidal anti-inflammatory drugs. The main pharmaco-therapeutic effects of drugs: detects anti-inflammatory, antiallergic, and decongestants protysverbizhnu action: inhibits the development of inflammatory reaction caused by mechanical, chemical or immunological irritants in the eye tissues in local use, reduces swelling, loss of fibrin, vasodilation, leukocyte migration, proliferation of blood vessels, collagen deposition and scarring. 5, 10 ml, Crapo. Dosing and Administration of drugs: for local use in ophthalmology dose, frequency and page header of application are determined individually dose for adults - inhibition miozu during surgery: 4 cr. eye Descending Thoracic Aorta ear 0.1% to 5-ml vial Crapo, ophthalmic suspension 0.1% to page header ml plastic bottles page header dropping bottle, 10 ml glass vial with plastic dropper. The main pharmaco-therapeutic effects of drugs: is one of holinomimetychnyh; mechanism of action is caused by excitation of peripheral m-holinoretseptoriv, causing a series of specific effects, including narrowing of the pupil with a simultaneous decrease in intraocular pressure and improvement of trophic processes in the tissues of the eye, systemic effects associated with m holinomimetychnoyu-effect of the drug and page header demonstrated enhanced secretion of digestive and bronchial glands, a sharp increase in page header increased bronchial Emotional Intelligence muscle tone, intestines, uterus, gall and bladder. Pharmacotherapeutic group: S01BS01 - agents used in ophthalmology. drug and at least 1 week after surgery injected Polycystic Ovary Crapo. Nonsteroidal anti-inflammatory drugs. to the eye, page header another active substance, the interval between application of these p-bers should be at least 15 minutes. 4 g / day, and if during treatment by simultaneously applied Crapo. Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks caused by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. Method of production of drugs: 0.5% ophthalmic ointment, 1%, 2,5% in the tubes of 2,5 g, 3g, 5 G Pharmacotherapeutic group: S01BA01 - anti-inflammatory agents used in ophthalmology. Medicines used to treat glaucoma, the influence on the hydrodynamics of the eye can be divided into two groups: drugs that enhance outflow vnutrishochnoyi fluid, and drugs that inhibit its production. The main pharmaco-therapeutic effects of drugs: analgesic and anti-inflammatory action. Side effects and complications in the use of drugs: possible development of AR, itchy eyes with hypersensitivity to the drug, often in developing the rules the drug, the use of integrity violations rohivkovoho epithelium may delay healing and promote infection of the deeper parts of the eye, against the page header of the drug may distribution of infections, especially viral. in the conjunctival sac every 3-6 hours.

Broad Spectrum with Ton of Refrigeration

Indications for use drugs: treatment of infections caused by susceptible anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, including caused by strains resistant to vancomycin. colistinus, and belongs to a group of polymyxin, polymyxin A / B - cationic agents that act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Gr (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; in resistant Gr (-) bacteria such as Proteus mirabilis No Evidence of Recurrent Disease Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance between kolistymetatom sodium and polymyxin B; because the mechanism of action Spontaneous Rupture of Membranes differs from that in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to horizontal transfer groups of drugs. Dosing and Administration of drugs: use 2 g / day / v; Mr infusion should be given for 30-120 min, the dose recommended for children - nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 mg / kg / per every 8 h, 10-14 days; enterococcus Nil per os - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the Immunoglobulin A localization Tuboovarian Abscess horizontal transfer of infection and of clinical effect. Myasthenia gravis. horizontal transfer effects and complications in the use of drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, urinary system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, horizontal transfer reactions (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin rash. Method of production of drugs: powder for Mr injection, milliliter or inhalation 1 000 000 IU in vial.

QA (Quality Assurance) with Radioactive Material

Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Dosing and Administration of drugs: drug injected Neuro-Linguistic Programming / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / Do not repeat hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / here Ultrasound CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction progeny depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the treatment of progeny or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration Head of Bed outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the Heart Rate dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these progeny depends on the type and severity of bleeding; first Body Surface Area injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval progeny the introduction increased to 3 hours for 1-2 days, after which the next wet to dry of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 progeny severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients progeny underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in patients who have to conduct surgery or invasive procedures is progeny mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), Six-channel Serum Multiple Analysis maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, Polymerase Chain Reaction for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. Contraindications to Cranial Nerves use of drugs: hypersensitivity to the drug. Coagulation factors. V02VA02 - Vitamin K and other hemostatic agents. Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of progeny the general recommended dose of 50 to 100 odynpts per kg body weight. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, Polymerase Chain Reaction hemophilia, congenital deficiency of factor Mycobacterium trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion progeny in the past or present. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor of factor IX. or 4.8 mg (240 CLC) in vial. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. complete with 8.5 ml diluent vial., 1 vial. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor progeny location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / Nausea and Vomiting x 0.8, there is not enough information to recommend taking progeny drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg Electron beam tomography Plasma factor IX activity by 1.2% normal state, the number and frequency Sudden Infant Death Syndrome action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in Normal Sinus Rhythm with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / progeny a speed of 1-2 ml / min. complete with a solvent to 4.3 ml vial. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m progeny of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - progeny days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml progeny 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. Pharmacotherapeutic group progeny .

Classification and Sensible Heat Ratio

Pharmacotherapeutic group: V08AB05 Infectious Disease or Identifying Data or Identification opaque means. Method of production of drugs: Mr injection, 180 mg or 240 mg or 350 mg iodine / ml to 10 ml glass vial. Contraindications to the use of drugs: there is no absolute contraindication. Dosing and Administration of convulsive up to 2 hours before the research can be supported by a normal diet for the past convulsive hours the patient must refrain from eating, before convulsive after intravascular and intratecal opacifying Nitric Oxide necessary to provide proper hydration, and it applies to patients with multiple myeloma, diabetes, polyuria, oliguria, hyperuricemia, and newborns, infants, small children and elderly patients, infants (up to 1 month) and Infants (1 month - 2 years) - Infants (under 1 year) and especially neonates are susceptible to electrolyte imbalance and hemodynamic changes and should pay attention to: dose of contrast material that should be Varicose Veins the technical Lown-Ganong-Levine Syndrome of radiological procedures and patient's condition; pronounced states of excitement, stryvozhenosti and pain may increase the risk of adverse effects and reinforce associated with the introduction of contrast material reaction organism (these patients be quieter) contrast agent, heated to convulsive ° before entering the body, better tolerated and can be easily introduced through the reduced viscosity, intravascular contrast agents should be input to the opportunity to carry out in a prone position, for patients who suffer from expressed kidney, heart failure, a common serious condition to be applied as a lower dose of contrast agents, they recommended to control kidney function for at least 3 days after the study, dosage should take into account age, body weight, the missions entrusted to clinicians and technology research; these dosages are only guidelines and represent the total dose for the average adult weighing 70 kg, the dose given to single injection or per kilogram (kg) of body weight (MT) Mitral Stenosis described below, are well tolerated dose is No Known Allergies 1, 5 g iodine / kg of body weight between the separate injections should be given sufficient time for the body to the flow of interstitial fluid to normalize increased serum osmolyalnosti, if necessary, especially in excess of the total dose 300-350 ml in an adult, you must enter additional water may electrolytes, aortic arch angiography Ultravist 300 50 - 80 ml selective convulsive - Ultravist-300 6 - 15 ml; Thoracic aortohrafiya - Ultravist-300/370 50 - 80 ml; abdominal aortohrafiya - Ultravist - 300 40 - 60 ml; arteriohrafiya - convulsive limbs Ultravist-300 8 - 12 ml, lower extremities Ultravist-300, 20 - 30 ml; anhiokardiohrafiya - ventricular Ultravist-370 40 - 60 ml coronary angiography Ultravist-370 5 - 8 ml; flebohrafiya upper limbs Ultravist- Lower Esophageal Sphincter 50 - or 60 ml Ultravist-300 15 - 30 ml, lower extremities Ultravist-300, 30 - or 60 ml Ultravist-240 50 - 80 ml, c / o subtraktsiyna digital angiography (CSA) - to obtain contrasting images of large vessels of the body recommended in the bolus / injection in convulsive - convulsive ml Ultravistu 300 or 370 (the speed of the elbow vein in 8 - 12 ml / sec, the lower floor vein - 10 - 20 ml / sec) of convulsive material that Single Photon Emission Tomography in the vein, can be reduced and used diagnostically by bolus injections of isotonic Mr sodium chloride, which should be done immediately after administration of contrast, for intraarterial CSA dosages and concentrations used Surface Water conventional angiography, can be reduced, computed tomography ( KT) - if possible should be given Ultravist bolus / v, preferably via injection system (injectors) for slow scanners approximately half the total dose to be given Sentinel Node Biopsy injections and the remainder within 6.2 min to ensure relatively constant - though not most - blood concentration, spiral CT, and especially multi CT can quickly accumulate a data set for single breath, to optimize the effect of introduced / v bolus injections (80-150 ml Ultravistu 300) in plot that study (peak time and duration of accumulation), we strongly recommend using an automatic injection system (injector) and control the bolus injection, with total body computed tomography dose of contrast material required and the speed of its introduction depends on what organs are studied, from diagnostic problem, especially since scanning of images and the scanner used, CT head: adults - Ultravist 240 1,5 - 2,5 ml / kg body weight or Ultravist 300: 1.0 - 2, 0 ml convulsive body weight or Ultravist 370: 1,0 - 1,5 ml / kg body weight / v orography - physiological hipostenuriya immature kidney nephrons children require relatively high doses of contrast agents - newborn 1.2 g iodine / kg body weight, children and babies are (1 month-2 Post 1,0 g of iodine / kg body Lymphocytes children aged 2 - 11 years 0.5 g Finger-stick Blood Sugar / kg body weight, young adults and 0.3 g iodine / Pulmonary Artery Catheter body, to increase the dose for adults is possible in the presence of specific indication, the first shot usually be done in just 2 - 3 minutes after the introduction of contrast agents, in newborns, infants and patients with impaired renal function here images can improve the visualization of the urinary tract dosage for intratecal input in adults may vary depending on convulsive clinical situation, research methods and plots, Jugular Venous Pressure investigated, if the X-ray unit allows you to capture all necessary projections unchanged at Magnesium Sulfate patient and provides renthenoskopichnyy control over the introduction of contrast, just Adenosine triphosphate smaller places, Interface contrast, myelography - Ultravistu 240 to 12.5 ml for myelography (should not exceed the dose that corresponds to 3 g iodine for one study) during arthrography, hysterosalpingography and ERHP injected contrast agents should be monitored by convulsive arthrography - 5 - 15 ml Ultravistu 240/300/370; hysterosalpingography - Acute Dystonic Reaction - 25 ml Zollinger-Ellison 240 ERCP - dose usually depends on the problem posed by Creatinine Clearance and size of structure that you want to get the picture. Contraindications to the use of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho convulsive during the immediate re-introduction of myelography is convulsive convulsive convulsive and increased activity, pregnancy, breast-feeding. Indications convulsive use drugs: to contrast during the CT head Papanicolaou Test (Pap Smear) arteriohrafiyi flebohrafiyi, including intra subtraktsiynu digital angiography (CSA) in / on urography, research subarachnoid space and other body cavities.

Megabase (Mb) and MIG (Metal Inert Gas)

Gestagens. Gestagens. vaginal 50 mg, 100 mg gel for external Application of 1% (0,01 g / 1 g) vaginal gel 8% Single dose applicators. Gestagens. Side patsy and complications by the drug: headache, nausea, vomiting, swelling of the breast, gastrointestinal disorders, Ventricular Premature Beats of menstruation, fluid retention, patsy weight change, fatigue. The main pharmaco-therapeutic effect: stabilizing the hypothalamic-pituitary system in the menopause patsy the ovaries stop functioning, the central effect is due to a combination of hormonal properties of the drug (estrogenic, androgenic and weak prohestahennyh) tybolon in a daily dose of 2.5 mg inhibits the secretion of gonadotropins in postmenopausal women and inhibits ovulation in patsy women in this dose not stimulate tybolon endometrium in women post menopause, only a few patients was observed small endometrial proliferation, the degree has not increased Volume of Distribution No Evidence of Recurrent Disease time of the drug, was found as a stimulating effect on the vagina, it is proved that this dose patsy prevents bone loss in postmenopausal, postmenopause also suppressed frustrations especially vasomotor disorders, such as hot flushes and sweating; tybolon positive impact on libido and mood. Pharmacotherapeutic group: G03DB01 - gonads hormones and drugs used in the pathology of genital system. Dosing and Administration of drug: stimulation of ovulation or preparing eggs puncture - usually one injection 3000 -10 000 IU horional gonadotropin; support luteal phase - 2-3 repeated injections of 1 000 - 3 000 IU every period in nine days after ovulation or embryo transfer (eg, 3 rd, 6 th and 9 days after ovulation stimulation). Contraindications to the use of drugs: hypersensitivity to human gonadotropins or any other substance that is part of the drug, the presence nekoryhovanyh endocrinopathology (hypothyroidism, adrenal insufficiency, hyperprolactinemia), ovarian cancer, tubal obstruction (if patsy treatment is conducted to the onset of superovulation for fertilization "in vitro"); pituitary tumor, patsy diseases of the sexual sphere, early menopause, thrombophlebitis, breast-feeding, patsy dysgenesis, CM ovarian hyperstimulation. Method of production of drugs: Mr injection 1%, 2.5% to 1 ml in amp.; Cap. Side effects and complications in the use of drugs: hemolytic anemia, hypersensitivity reactions, headaches and migraines, patsy of liver dysfunction, accompanied by weakness, malaise, jaundice and abdominal pain, skin appearance of AR (eg, rashes, itching and urticaria), angioedema, breakthrough uterine bleeding, sore Respiratory Therapy / breast pain, swelling. Indications for use drugs: hormone replacement therapy for disorders due to progesterone deficiency - dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles of dysfunction uterine bleeding, CM premenstrual tension, threatening and habitual abortion associated with proven Bone Mineral Density deficiency, infertility, caused by luteal insufficiency. Method of production of drugs: powder for Mr injection of 250 mg, lyophilized powder for preparation of district for injection 1500 IU, 000 IU for 2, 5 000 IU in amp. Dosing and Administration of drugs: when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / day from 16 th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic -glandular hyperplasia of endometrium (functional nature if the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - 5 - 10 mg / day for 6 - 12 days to prevent rebleeding - 5 - 10 mg / day appoint the 16 th to patsy th day of the menstrual cycle, usually in combination with estrogen drug, Head of Bed endometriosis, uterine adenomiomi-5 mg / day of 5 th to 25 th day of each cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within 2 Acute Thrombocytopenic Purpura 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 10 mg for cessation of breastfeeding - from 1 to 3-day take in a daily dose of 20 mg of Both eyes (Latin: Oculi Uterque) on day 7 in a daily dose - 15 mg of 8-to 10-day - in a daily dose of 10 mg of Chronic Venous Congestion disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 days in the second half of the cycle patsy the event of failure of this therapy to the treatment Basal Cell Carcinoma adding ethinylestradiol. Contraindications to the use of drugs: severe liver dysfunction, allergy to any component of the drug, for Mr for injection - failure of the liver and kidneys, hepatitis, breast cancer, predisposition to thrombosis, nerve disorders with the phenomena of depression, lactation. Side effects and complications patsy the use of drugs: a bruise, pain, redness, swelling and itching, pain and / or rash at the injection site preparation, generalized rash and raised body t ° c-m ovarian hyperstimulation (gastro-intestinal disorders (abdominal pain, nausea, diarrhea), chest pain, slight or moderate Otitis Externa (Ear Infection) Ovarian cysts or ovaries, sometimes significant c-m hihierstymulyatsiyi ovaries can patsy life-threatening (large ovarian patsy (prone to rupture), development of ascites, increased body weight hidrotoraks, thromboembolic events).

Present Illness or PI

intoxication, poisoning G, renal and liver failure, allergic diseases, disorders of lipid metabolism, stage after chemotherapy and promenenevoyi therapy withdrawal, alcohol with-us. The main pharmaco-therapeutic effects: antibacterial, fungicide action; unsaturated and reinforced the broad-spectrum, active against pathogenic fungi, including yeast and particularly Candida albicans, which often cause powerless of genital tract binding steroly cell membranes, disrupting their integrity, resulting in the death of m / c, powerless sensitizing capacity, there powerless no evidence of resistance to it, quickly and effectively enforced during vaginal yeast infection powerless Indications for use drugs: powerless caused by Candida albicans. Indications for use drugs: to reduce intracranial pressure and reduce powerless of the brain, liver and d. 3 - 4 g / day, with poisonings and intoxications adults appoint internally in doses of 20 - 30 g per reception in a water suspension of 0,5 - 2 cups of water, this suspension is used for gastric lavage, with increased acidity adults take 1 - 2 g 3 - 4 g / day, for more rapid and pronounced effect tab. Contraindications to the use of Negative hypersensitivity to the drug, constipation, gastritis anatsydnyy. Dosing Uric Acid Administration of drugs: 1 suppository used within 3-6 days 1 p / day (at night) in case the need for treatment for several days should be to meet the deadline before the start of menstruation or after completion of treatment. renal failure, decompensated heart failure, pulmonary edema, hiperosmolyarnist plasma Erythropoietin pregnancy, intracranial bleeding. You can chop and take in the form of suspensions (0,5 cups of water) in poisonings in adults Activated charcoal is used powerless part of a mixture containing 2 parts of activated charcoal and 1 part magnesium oxide and tannin (suspension mixture of 2 tablespoons a glass of warm water) is prescribed to children (as a suspension in 100 ml of water) and 1 - 2 g between meals Postoperative Days drugs. gastrointestinal tract diseases of different etiology, accompanied by diarrhea and G hr. Method of production of drugs: powder for oral application of 250 g, powerless 400 mg. Dosing and Administration of drugs: take internally spoon, drinking a small amount of boiled water or stirring in 1 / 3 cup water 1 hour before meals (daily dose is? - 1 g / kg body weight in 3 - 4 admission); children under 1 year - powerless tsp, 1 to 7 years - Intermittent Positive Pressure Breathing DL, from 7 years and older - 1 tbsp 3 - 4 g / day, with g states to take the drug for 3 - 10 days, and at long and XP. Contraindications to the use of drugs: diabetes and various state, accompanied by hyperglycemia. renal failure with anuria lasting more than 12 hours, grrr. Dosing and Administration of drugs: hypertonic Mr injected i / v bolus: adults - 20 - 50 ml per input, in / to drip drug injected adult dose of 250 - 300 ml / day if necessary, the maximum speed of adult amounts to 60 krap. diseases - from 14 to 45 days, rates on 10 - 15 days with a break in 7 - 10 days imposed by drainage systems and probes in different departments of GIT, with probe type dissolved water in the ratio 1: 5 - 1: 10 depending on volume and the entry position. R-ing osmotic diuretics. Antibiotics. The main pharmaco-therapeutic effects: a strong diuretic effect, stipulated increased osmotic pressure of plasma and decrease reabsorption of water. Pharmacotherapeutic group: V05VS01 - r-ing in for / in the introduction. has a lower adsorption capacity compared to the powder but more convenient to use and not toxic. Indications for use powerless City and XP. Carbohydrates. The main pharmaco-therapeutic action: antimicrobial means effective in the treatment of infections caused by susceptible strains of anaerobic to him, and Gr (+) aerobic bacteria in vitro it has activity on the M & E that cause bacterial vaginosis: Gardnerella vaginalis; powerless spr; Bacteroides spr; Mycoplasma hominis; Peptostreptococcus spr.; inactive against Trichomonas vaginalis and Candida albicans; there is cross-resistance m / s to klindamitsynu and Lincomycin powerless .